The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Multiple sclerosis (MS) is a neurological disease that affects about 1 million people in the United States. Your brain contains a type of cell called a neuron, and neurons are coated in a layer of ...

Join the School of Medicine’s Department of Population and Quantitative Health Sciences to learn about the options available with an MS in clinical research. A webinar will be held Sunday, Dec. 20, at ...

The first-ever adaptive clinical trial for Australians living with MS will seek to reverse neurological damage caused by progressive multiple sclerosis. With an initial $4 million in funding, the ...

MS is the most common demyelinating disease with an estimated prevalence of 3 in 1000 in the United States. It affects approximately 740,000 individuals in the United States and 2.5 million globally.

The Combined Bachelor’s/Master’s Degree program (CBM) is intended for highly motivated current CWRU undergraduate students who are candidates for any bachelor's ...

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...

Professional societies of neurologists, including most prominently the American Academy of Neurology (AAN) and the European Academy of Neurology (EAN) periodically release recommendations to guide ...

Multiple sclerosis (MS) is characterized by a broad array of symptoms. Despite this variability, most individuals with MS will exhibit a distinct set of symptoms during their initial clinical attack.